Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 2 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Multi-Targeted Therapies - Overview | 6 | 5 |
| Introduction | 6 | 1 |
| Biological Networks | 6 | 1 |
| Many Diseases are Caused by Multiple Factors | 6 | 1 |
| Networks are Robust | 6 | 1 |
| Not All Components of a Network are Equally Important | 7 | 1 |
| Drug Efficacy and Robustness | 7 | 1 |
| Multiple Weak Interactions | 7 | 1 |
| Impact of Networks for Drug Design | 7 | 1 |
| History of Multi-component Drugs | 8 | 1 |
| Types of Multi-Targeted Therapy | 8 | 1 |
| Many Small Molecule Drugs are Promiscuous | 9 | 1 |
| Off-target Effects and Drug Repositioning | 9 | 1 |
| Promiscuous Drugs versus Combination Therapies | 10 | 1 |
| Designing Multi-Target Drugs | 11 | 5 |
| Lead Generation Approaches | 11 | 1 |
| Knowledge-based Approaches | 11 | 1 |
| Text Mining | 11 | 1 |
| Network Analysis | 11 | 1 |
| Framework Combination | 11 | 1 |
| Screening | 12 | 1 |
| High-Throughput Screening | 12 | 1 |
| Focused Screening | 12 | 1 |
| Fragment-based Approach | 12 | 1 |
| In Silico Screening Methods | 12 | 1 |
| Molecular Docking | 12 | 1 |
| Pharmacophores | 13 | 1 |
| Machine Learning Methods | 13 | 1 |
| Conclusions | 13 | 1 |
| Challenges of Lead Optimization | 14 | 1 |
| Activity Profile | 14 | 1 |
| Physicochemical Properties | 14 | 1 |
| Multi-Target Protein Kinase Inhibitors | 14 | 1 |
| Early Marketed Kinase Inhibitors | 14 | 1 |
| Newer Designed Multi-kinase Inhibitors | 15 | 1 |
| Oncogene Addiction | 15 | 1 |
| Overcoming Resistance | 15 | 1 |
| Designing Combination Therapies | 16 | 6 |
| Which Products to Combine? | 16 | 1 |
| Cell-based Phenotypic Assays | 16 | 1 |
| Synthetic Lethality | 16 | 1 |
| Designing Dual Novel Drug Combinations | 17 | 1 |
| Challenges for Development and Design of Combination Drugs | 18 | 1 |
| Combined Toxicity | 18 | 1 |
| FDA Guidelines for Development of Drugs for Use in Combination | 18 | 1 |
| Combinations of Two or More Previously Marketed Drugs/Biologics | 18 | 1 |
| Combinations of Drugs/Biologics When One or More is Previously Marketed and One is a NME | 18 | 1 |
| Co-development of Two or More Un-marketed Investigational Drugs for Use in Combination | 19 | 1 |
| Clinical Trial Design | 20 | 1 |
| Adaptive Trial Design | 20 | 1 |
| Developing Drugs in Collaboration | 21 | 1 |
| Pipeline Analysis of Late Stage Oncology Combination Therapies | 22 | 31 |
| Phase III Oncology Pipeline by Number of Drugs in Combination | 22 | 1 |
| Phase III Oncology Pipeline by Indication | 23 | 1 |
| Overall | 24 | 2 |
| Lung Cancer | 26 | 2 |
| Promising Combinations | 28 | 1 |
| Breast Cancer | 29 | 2 |
| Promising Combinations | 31 | 1 |
| Colorectal Cancer | 31 | 1 |
| Promising Combinations | 32 | 1 |
| Lymphoma | 33 | 1 |
| Promising Combinations | 34 | 1 |
| Multiple Myeloma | 35 | 1 |
| Promising Combinations | 36 | 1 |
| Ovarian Cancer | 37 | 1 |
| Promising Combinations | 38 | 1 |
| Prostate Cancer | 39 | 1 |
| Promising Combinations | 40 | 1 |
| Leukemia | 41 | 1 |
| Promising Combinations | 42 | 1 |
| Head and Neck Cancer | 43 | 1 |
| Promising Combinations | 44 | 1 |
| Squamous Cell Carcinoma | 45 | 2 |
| Other Oncology Indications | 47 | 6 |
| Appendix | 53 | 3 |
| Abbreviations | 53 | 1 |
| Sources | 53 | 1 |
| Research Methodology | 54 | 2 |
| Secondary Research | 54 | 1 |
| Primary Research | 54 | 1 |
| Expert Panel Validation | 55 | 1 |
| Contact Us | 55 | 1 |
| Disclaimer | 55 | 1 |
